tbuckley/cabot-search huggingface dataset:
Relationship between pericardial friction rub and effusion in pericarditis Shlomo Natan, Bart Jan Meursing, Evert J. P. Lamfers, Anton J. M. Oude Ophuis, Freek W. A. Verheugt. Heartcenter, University Medical Center, Nijmegen, The Netherlands, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
William Prout (1785-1850) analytical chemist
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peripheral arterial tonometry: A simplified technique for assessing endothelium-dependent vasomotion Jeffrey T. Kuvin, Ayan R. Patel, Kathleen A. Sliney, Jacob Sheffy, Robert P. Schnall, Natesa G. Pandian, Richard H. Karas, James E. Udelson. Tufts-New England Medical Center, Boston, MA
Journal: Journal of the American College of Cardiology (2001)
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study
Authors: Sabrina Welland, Catherine Leyh, Fabian Finkelmeier, André Jefremow, Kateryna Shmanko, Maria A. Gonzalez-Carmona, Arne Kandulski, Petia Jeliazkova, Jan Best, Thorben W. Fründt, Angela Djanani, Maria Pangerl, Andreas Maieron, Richard Greil, Christina Fricke, Disorn Sookthai, Rainer Günther, Andreas Schmiderer, Henning Wege, Marino Venerito, Ursula Ehmer, Martina Müller, Christian P. Strassburg, Arndt Weinmann, Jürgen Siebler, Oliver Waidmann, Christian M. Lange, Anna Saborowski, Arndt Vogel
Journal: Liver Cancer (2022)

Background Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients is insufficiently defined. The purpose of this study was to evaluate the efficacy of lenvatinib in a multi-center cohort (ELEVATOR) from Germany and Austria. Methods A retrospective data analysis of 205 patients treated with first-line systemic lenvatinib at 14 different sites was conducted. Overall survival, progression free survival, overall response rate and adverse event rates were assessed and analyzed. Results Patients receiving lenvatinib in the real-world setting reached a median overall survival of 12.8 months, which was comparable to the results reported from the REFLECT study. Median overall survival (mOS) and progression free survival (mPFS) was superior in those patients who met the inclusion criteria of the REFLECT study compared to patients who failed to meet the inclusion criteria (mOS 15.6 vs 10.2 months, HR 0.55, 95% CI 0.38-0.81, p=0.002; mPFS 8.1 vs 4.8 months HR 0.65, 95% CI 0.46-0.91, p=0.0015). For patients with an impaired liver function according to the Albumin-Bilirubin (ALBI) grade, or reduced ECOG performance status ≥2, survival was significantly shorter compared to patients with sustained liver function (ALBI grade 1) and good performance status (ECOG performance status 0), respectively (HR 1.69, 95% CI 1.07-2.66, p=0.023; HR 2.25, 95% CI 1.19-4.23, p=0.012). Additionally, macrovascular invasion (HR 1.55, 95% CI 1.02-2.37, p=0.041) and an AFP ≥200 ng/mL (HR 1.56, 95% CI 1.03-2.34, p=0.034) were confirmed as independent negative prognostic factors in our cohort of patients with advanced HCC. Conclusion Overall, our data confirm the efficacy of lenvatinib as first-line treatment and did not reveal new or unexpected side effects in a large retrospective Caucasian real-world cohort, supporting the use of lenvatinib as meaningful alternative for patients that cannot be treated with IO-based combinations in first-line HCC.
Radioactive stents inhibit neointimal hyperplasia and induce expansive remodeling in a dose-dependent pattern Paul Wexberg, Christian Kirisits, Mariann Gyongyosi, Michael Gottsauner-Wolf, Boris Pokrajac, Richard Potter, Dietmar Glogar. Division of Cardiology, University of Vienna Medical Center, Vienna, Austria, Department of Radiotherapy and Radiobiology, University of Vienna Medical Center, Vienna, Austria
Journal: Journal of the American College of Cardiology (2001)
The use of complementary and alternative medicine (CAM) by Irish patients with cancer.
Authors: N. A. O'Connor, D. M. Graham, J. McCaffrey, D. N. Carney
Journal: Journal of Clinical Oncology (2011)

e19618 Background: Worldwide, the use of complementary and alternative medicine (CAM) has greatly increased over the last decade. CAM use has been shown to be higher in cancer patients than among the general population. The WHO categorises CAM as non-medication and medication therapies, the latter of which is of particular interest to oncologists as these therapies may potentially interact with prescribed medications. Methods: In order to estimate the prevalence and patterns of use of CAM among Irish cancer patients, an anonymous cross-sectional survey was offered to all patients attending for treatment of malignancy or cancer-care follow-up at a single Irish Cancer Centre over an 8-week period. The reasons for CAM use and those factors that increase the likelihood of CAM use were also investigated. Results: A total of 230 questionnaires were distributed. 193 patients responded. Of these, 5 were excluded due to lack of demographic data. Of the 188 surveys available for analysis, 134 respondents were female (80%) and 91 (49%) had a diagnosis of breast cancer. 63 patients (34%) reported having used CAM. There was no significant relationship between gender or tumour type and CAM use. Of those who used CAM, 27 (45%) commenced CAM use following their cancer diagnosis. Respondents who were single (p=0.009), currently in employment (p=0.032) and receiving antibody therapies (p=0.023) were more likely to use CAM. The most common reason cited for CAM use was to improve physical well-being (48%) and 80% reported a benefit. The most commonly used therapies were massage/reflexology (54%), relaxation therapy (54%) and herbal teas (51%). CAM medication therapies were used by 43% of CAM-users, of whom 45% had not informed their doctor. Conclusions: CAM use is prevalent among Irish cancer patients, with our data showing it to be higher than that reported in the majority of other European countries. Use of CAM is more common in single, employed patients and in those receiving antibody therapies. A significant proportion use CAM medications, which may potentially interact with prescribed treatment. Of note, almost half of these patients do not inform their doctor. This underlines the need for physicians to ask about CAM use in all patients being treated for malignancy.
Neoadjuvant chemoradiotherapy with or without Pd-1 antibody sintilimab for pMMR/MSS/MSI-L locally advanced rectal cancer: A randomized controlled study (cohort B).
Authors: Weiwei Xiao, Jun-zhong Lin, Gong Chen, Xiao-Jun Wu, Zhen-Hai LU, Qiaoxuan Wang, Peiqiang Cai, Min Liu, LongJun He, ShaoYan Xi, Feng Wang, Huizhong Zhang, Yuan-Hong Gao, Zhi-Zhong Pan, Rui-hua Xu
Journal: Journal of Clinical Oncology (2022)

TPS210 Background: Neoadjuvant chemoradiotherapy (NACRT) could bring tumor downstaging and pathological response (pCR), and also survival benefit for locally advanced rectal cancer (LARC) patients. Several single arm prospective clinical trials have investigated combination effect of immunotherapy (PD-1 or PD-L1 antibody) and NACRT in LARC patients, such as the VOLTAGE clinical trial. A randomized trial is needed to confirm the benefit of immunotherapy in this setting and explore predictive biomarkers. This is a clinical trial with two cohorts according the MMR/MSI status (clinicalTrials.gov, NCT04304209). Methods: In this study, LARC patients with pMMR/MSS/MSI-L tumor will enter cohort B and be randomized into two arms. Main inclusion criteria include: cT3-4N0M0 or cTxN+M0 rectal adenocarcinoma, pMMR/MSS/MSI-L confirmed by immunohistochemistry or gene test, aged 18-75y; ECOG performance 0-1; no previous anti-tumor treatment for rectal adenocarcinoma. Main exclusion criteria include: active autoimmune diseases or a history of autoimmune diseases, and inadequate main organ functions. Patients in the experimental arm will receive four cycles of neoadjuvant PD1 antibody Sintilimab, Capeox chemotherapy and concurrent radiotherapy, followed by curative surgery or watch and wait, then four cycles of adjuvant Capeox chemotherapy. Patients in the control arm will receive four cycles of neoadjuvant Capeox chemotherapy and concurrent radiotherapy, followed by curative surgery or watch and wait, then four cycles of adjuvant Capeox chemotherapy Primary outcome measure is pCR rate. Secondary outcome measures include acute toxicity, tumor regression grade, R0 resection rate, local recurrence, distant metastasis. Sample size for this cohort is 134. Whole exome sequencing, RNA sequencing and immunohistochemistry of the rectal primary tumor are planned for biomarker searching and synergy effect mechanism investigation. The first patient has been enrolled in June, 2020. Clinical trial information: NCT04304209.
The authors reply
Authors: Edmund J. Lamb, Alice J. Sitch, Jonathan Barratt, Elizabeth A. Brettell, Paul Cockwell, R. Neil Dalton, Jon J. Deeks, Gillian Eaglestone, Tracy Pellatt-Higgins, Philip A. Kalra, Kamlesh Khunti, Fiona C. Loud, Frances S. Morris, Ryan S. Ottridge, Paul E. Stevens, Claire C. Sharpe, Andrew J. Sutton, Maarten W. Taal, Ceri Rowe
Journal: Kidney International (2019)
Interpreting Geroscience-Guided Biomarker Studies
Authors: Scott R. Bauer, John C. Newman
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Erratum: “A Probabilistic Approach to Evaluate the Risk of Decreased Total Triiodothyronine Hormone Levels following Chronic Exposure to PFOS and PFHxS via Contaminated Drinking Water”
Authors: Antero Vieira Silva, Joakim Ringblom, Christian Lindh, Kristin Scott, Kristina Jakobsson, Mattias Öberg
Journal: Environmental Health Perspectives (2020)
866-3 Assessment of left ventricular torsional deformation by doppler tissue imaging: A validation study using tagged magnetic resonance imaging
Authors: Yuichi Notomi, Randolph M Setser, Takahiro Shiota, Maureen G Martin-Miklovic, Jane M Kasper, Zoran B Popovic, Hirotsugu Yamada, Dimitri G Deserranno, Neil L Greenberg, Mario J Garcia, Richard D White, James D Thomas
Journal: Journal of the American College of Cardiology (2004)
Section 13.—Necrotizing Arteritis and Other Forms of Vasculitis
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychiatry
Authors: Schuyler W. Henderson
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to Peng He, Xiaohui Wang, and Hao Li’s Letter to the Editor re: Yu Xiao, Kaiyu Qian, Yongwen Luo, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03.025
Authors: Yu Xiao, Kaiyu Qian, Yongwen Luo, Song Chen, Mengxin Lu, Gang Wang, Lingao Ju, Xinghuan Wang
Journal: European Urology (2020)
Oral Contraceptives and Stroke in Young Women
Journal: JAMA (1975)

Oral contraceptive use alone, in the absence of smoking, hypertension, or migraine, significantly increases the risk of stroke. Regardless of use or nonuse of these agents, hypertension is a risk factor for development of either thrombotic or hemorrhagic stroke. Regular cigarette smoking and a history of symptoms indicative of migraine also increase the likelihood of one or the other type of stroke, but more information is needed before a definite relationship can be established between these clinical factors and cerebrovascular disease.
Changes in Isoniazid Resistance of Tubercle Bacilli after Cessation of Treatment: Report by the Laboratory Subcommittee of the Tuberculosis Chemotherapy Trials Committee, Medical Research Council M.R.C. ISONIAZID TRIAL: REPORT NO. 6
Journal: Thorax (1954)

The use of isoniazid in the treatment of pulmonary tuberculosis became widespread in the spring of 1952.It was soon shown that when this drug was given alone bacterial resistance developed frequently and rapidly (Medical Research Council, 1952); approximately two-thirds of positive cultures from patients at the end of a three-month course of isoniazid alone were resistant to the drug, many of them to a high degree.Much confirmatory evi- dence followed from other countries (Dye, 1953; Ferebee and Long, 1953; Lotte and Poussier, 1953; Swedish National Association Against Tuberculosis, 1953).There were also early reports that strains which developed resistance to isoniazid in vitro might revert to sensitivity when contact with isoniazid ceased (Pansy, Stander, and Donovick, 1952; Bamett, Bushby, and Mitchison, 1953a).These reports were followed by others presenting evidence that after treatment with isoniazid had been discontinued resistant cultures from patients might also revert either to a lower level of resistance or to full sensitivity (Nitti, 1952;Ashino, 1953;Nigoghossian, 1953; Petit, 1953a Petit, , 1953b).These observations were in clear contrast to the usual persistence of streptomycin-resistant strains in patients following treatment with streptomycin alone (Tucker, 1949; Canada, Allison, D'Esopo,
Rats, Not Guinea-Pigs, Used for Testing Arsphenamin.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P202: Non-targeted Metabolomics Study Identify Multiple Metabolites Associated With Body Mass Index
Authors: Shengxu Li, Changwei Li, Tanika N Kelly, Xiaoying Gu, Xiao Sun, Lydia Bazzano, Wei Chen, Paul K Whelton, Jiang He
Journal: Circulation (2018)

Background: Non-targeted metabolomics technology provides a powerful tool to examine the complex etiology of obesity and the underlying mechanisms for its health consequences. The current study aimed to examine the associations of metabolites, quantified by non-targeted metabolomics technology, with body mass index (BMI) in the Bogalusa Heart Study. Methods: The study included 1,261 participants (825 White and 436 Blacks) aged 34-58 years. General linear models were used to examine the associations of BMI with the 1,202 metabolites that passed rigorous quality control measures, adjusted for age, sex, smoking, drinking, education, and total physical activity in Blacks and Whites, separately. Weighted correlation network analysis (WGCNA) was used to build metabolites modules according to pair-wise correlations (signed positive correlation and unsigned correlation regardless of correlation direction) among all metabolites; partial correlation was used to assess the link between each module and BMI. Results: Six-eight metabolites showed Bonferroni-corrected (P &lt; 4.16E-5) associations with BMI in both Blacks and Whites. The most significant metabolite was glutamate (P = 1.52E-12 in Blacks and P = 1.47E-37 in Whites). Among the 46 significant metabolites with known identities, a majority were involved in pathways of lipids (22 metabolites) and amino acids (13 metabolites). Fifteen unsigned metabolites modules were identified and six of the modules showed significant correlation with BMI (absolute r = 0.11-0.14); ten signed metabolites modules were identified and five of them were significantly correlated with BMI (absolute r = 0.14-0.31). Conclusion: We have identified multiple metabolites robustly associated with BMI, which have novel biological implications for obesity and its health consequences.
Autoinflation may help in glue ear, but the evidence is poor
Journal: BMJ (1999)

Haemophilus influenzae type b vaccine is not linked to diabetes Environmental risk factors for type 1 diabetes remain unknown.It has been speculated that some vaccines might trigger it, although data are lacking.On p 1169 Karvonen et al describe their findings from a nationwide randomised study on the association between Haemophilus influenzae type b vaccination and type 1 diabetes in Finland, which has the highest incidence of type 1 diabetes.The risk of type 1 diabetes during the first 10 years of life was similar in children vaccinated with H influenzae type b at 3 months and those immunised at 24 months only.Moreover, the incidence of the disease in the immunised children was no different from that in those children born during the two years before the start of the vaccination programme.It is unlikely that H influenzae vaccination causes type 1 diabetes in children.
Error in Abstract Results
Authors: Thomas Hank, Marta Sandini, Carlos Fernández-Del Castillo, Carlos Fernández-Del Castillo
Journal: JAMA Surgery (2020)

Joyce V. Veld, MD, MSc; Femke J. Amelung, MD, PhD; Wernard A. A. Borstlap, MD, PhD; Emo E. van Halsema, MD, PhD; Esther C. J. Consten, MD, PhD; Peter D. Siersema, MD, PhD; Frank ter Borg, MD, PhD; Edwin S. van der Zaag, MD, PhD; Johannes H. W. de Wilt, MD, PhD; Paul Fockens, MD, PhD; Wilhelmus A. Bemelman, MD, PhD; Jeanin E. van Hooft, MD, PhD, MBA; Pieter J. Tanis, MD, PhD; for the Dutch Snapshot Research Group